EIF2AK3 and melanoma: After confirming that LY-4 inhibits PERK activity in cultured melanoma cells (Fig 4A), mice were exposed to tamoxifen to induce BRAFV600E and delete a single Perk allele; LY-4 treatment was initiated when tumors were 2-3mm3.